1	Islet	Islet	B-NP	NN	O	3	NMOD	0
2	endothelial	endothelial	I-NP	JJ	O	3	NMOD	0
3	activation	activation	I-NP	NN	O	8	NMOD	17	activation
4	and	and	O	CC	O	8	NMOD	0
5	oxidative	oxidative	B-NP	JJ	O	8	NMOD	0
6	stress	stress	I-NP	NN	O	8	NMOD	0
7	gene	gene	I-NP	NN	O	8	NMOD	0
8	expression	expression	I-NP	NN	O	9	SUB	0
9	is	be	B-VP	VBZ	O	0	ROOT	0
10	reduced	reduce	I-VP	VBN	O	9	VC	18	reduced
11	by	by	B-PP	IN	O	10	VMOD	0
12	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	13	NMOD	0
13	treatment	treatment	I-NP	NN	O	11	PMOD	19	treatment
14	in	in	B-PP	IN	O	13	NMOD	0
15	the	the	B-NP	DT	O	20	NMOD	0
16	type	type	I-NP	NN	O	20	NMOD	0
17	2	2	I-NP	CD	O	20	NMOD	0
18	diabetic	diabetic	I-NP	JJ	O	20	NMOD	0
19	GK	GK	I-NP	NN	O	20	NMOD	0
20	rat	rat	I-NP	NN	O	14	PMOD	0
21	.	.	O	.	O	9	P	0

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Inflammation	Inflammation	B-NP	NN	O	7	SUB	0
4	followed	follow	B-VP	VBN	O	3	NMOD	0
5	by	by	B-PP	IN	O	4	VMOD	0
6	fibrosis	fibrosis	B-NP	NN	O	5	PMOD	0
7	is	be	B-VP	VBZ	O	1	NMOD	0
8	a	a	B-NP	DT	O	9	NMOD	0
9	component	component	I-NP	NN	O	7	PRD	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	islet	islet	B-NP	NN	O	12	NMOD	0
12	dysfunction	dysfunction	I-NP	NN	O	10	PMOD	6	dysfunction
13	in	in	B-PP	IN	O	7	VMOD	0
14	both	both	O	CC	O	20	NMOD	0
15	rodent	rodent	B-NP	NN	O	20	NMOD	0
16	and	and	O	CC	O	20	NMOD	0
17	human	human	B-NP	JJ	O	18	NMOD	0
18	type	type	I-NP	NN	O	20	NMOD	0
19	2	2	B-NP	CD	O	18	NMOD	0
20	diabetes	diabete	I-NP	NNS	O	13	PMOD	0
21	.	.	O	.	O	7	P	0

1	Because	Because	B-SBAR	IN	O	11	VMOD	0
2	islet	islet	B-NP	NN	O	3	NMOD	0
3	inflammation	inflammation	I-NP	NN	O	4	SUB	0
4	may	may	B-VP	MD	O	1	SBAR	0
5	originate	originate	I-VP	VB	O	4	VC	0
6	from	from	B-PP	IN	O	5	VMOD	0
7	endothelial	endothelial	B-NP	JJ	B-cell_type	8	NMOD	0
8	cells	cell	I-NP	NNS	I-cell_type	6	PMOD	0
9	,	,	O	,	O	11	P	0
10	we	we	B-NP	PRP	O	11	SUB	0
11	assessed	assess	B-VP	VBD	O	0	ROOT	0
12	the	the	B-NP	DT	O	13	NMOD	0
13	expression	expression	I-NP	NN	O	11	OBJ	0
14	of	of	B-PP	IN	O	13	NMOD	0
15	selected	select	B-NP	VBN	O	16	NMOD	0
16	genes	gene	I-NP	NNS	O	14	PMOD	0
17	involved	involve	B-VP	VBN	O	16	NMOD	0
18	in	in	B-PP	IN	O	17	VMOD	0
19	endothelial	endothelial	B-NP	JJ	B-cell_type	21	NMOD	0
20	cell	cell	I-NP	NN	I-cell_type	21	NMOD	0
21	activation	activation	I-NP	NN	O	18	PMOD	17	activation
22	in	in	B-PP	IN	O	21	NMOD	0
23	islets	islet	B-NP	NNS	O	22	PMOD	0
24	from	from	B-PP	IN	O	23	NMOD	0
25	a	a	B-NP	DT	O	27	NMOD	0
26	spontaneous	spontaneous	I-NP	JJ	O	27	NMOD	0
27	model	model	I-NP	NN	O	34	NMOD	0
28	of	of	B-PP	IN	O	27	NMOD	0
29	type	type	B-NP	NN	O	31	NMOD	0
30	2	2	I-NP	CD	O	31	NMOD	0
31	diabetes	diabete	I-NP	NNS	O	28	PMOD	0
32	,	,	O	,	O	34	P	0
33	the	the	B-NP	DT	O	34	NMOD	0
34	Goto-Kakizaki	Goto-Kakizaki	I-NP	NNP	O	24	PMOD	0
35	(	(	O	(	O	37	DEP	0
36	GK	GK	B-NP	NN	O	37	DEP	0
37	)	)	O	)	O	34	NMOD	0
38	rat	rat	B-NP	NN	O	34	NMOD	0
39	.	.	O	.	O	11	P	0

1	We	We	B-NP	PRP	O	3	SUB	0
2	also	also	B-ADVP	RB	O	3	VMOD	0
3	examined	examine	B-VP	VBD	O	0	ROOT	0
4	islet	islet	B-NP	NN	B-DNA	12	NMOD	0
5	endotheliuml/oxidative	endotheliuml/oxidative	I-NP	JJ	I-DNA	12	NMOD	0
6	stress	stress	I-NP	NN	I-DNA	12	NMOD	0
7	(	(	I-NP	(	I-DNA	12	NMOD	0
8	OS	OS	I-NP	NN	I-DNA	12	NMOD	0
9	)	)	I-NP	)	I-DNA	12	NMOD	0
10	/inflammation-related	/inflammation-related	I-NP	JJ	I-DNA	12	NMOD	0
11	gene	gene	I-NP	NN	I-DNA	12	NMOD	0
12	expression	expression	I-NP	NN	O	17	NMOD	0
13	,	,	O	,	O	17	P	0
14	islet	islet	B-NP	NN	O	15	NMOD	0
15	vascularization	vascularization	I-NP	NN	O	17	NMOD	3	vascularization
16	and	and	O	CC	O	17	NMOD	0
17	fibrosis	fibrosis	B-NP	NN	O	3	OBJ	0
18	after	after	B-PP	IN	O	3	VMOD	0
19	treatment	treatment	B-NP	NN	O	18	PMOD	19	treatment
20	with	with	B-PP	IN	O	19	NMOD	0
21	the	the	B-NP	DT	O	27	NMOD	0
22	interleukin-1	interleukin-1	I-NP	NN	B-protein	27	NMOD	0
23	(	(	O	(	O	25	DEP	0
24	IL-1	IL-1	B-NP	NN	B-protein	25	DEP	0
25	)	)	O	)	O	22	NMOD	0
26	receptor	receptor	B-NP	NN	O	27	NMOD	0
27	antagonist	antagonist	I-NP	NN	O	20	PMOD	0
28	(	(	O	(	O	30	DEP	0
29	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	30	DEP	0
30	)	)	O	)	O	27	NMOD	0
31	.	.	O	.	O	3	P	0

1	METHODOLOGY/PRINCIPAL	METHODOLOGY/PRINCIPAL	B-NP	NN	O	2	NMOD	0
2	FINDINGS	FINDINGS	I-NP	NNS	O	6	SUB	0
3	:	:	O	:	O	2	P	0
4	Gene	Gene	B-NP	NN	O	5	NMOD	0
5	expression	expression	I-NP	NN	O	6	SUB	0
6	was	be	B-VP	VBD	O	0	ROOT	0
7	analyzed	analyze	I-VP	VBN	O	6	VC	0
8	by	by	B-PP	IN	O	7	VMOD	0
9	quantitative	quantitative	B-NP	JJ	O	10	NMOD	0
10	RT-PCR	RT-PCR	I-NP	NN	O	8	PMOD	0
11	on	on	B-PP	IN	O	7	VMOD	0
12	islets	islet	B-NP	NNS	O	11	PMOD	0
13	isolated	isolate	B-VP	VBN	O	12	NMOD	19	isolated
14	from	from	B-PP	IN	O	13	VMOD	0
15	10-week-old	10-week-old	B-NP	JJ	O	17	NMOD	0
16	diabetic	diabetic	I-NP	JJ	O	17	NMOD	0
17	GK	GK	I-NP	NN	O	21	NMOD	0
18	and	and	I-NP	CC	O	21	NMOD	0
19	control	control	I-NP	NN	O	21	NMOD	0
20	Wistar	Wistar	I-NP	NNP	O	21	NMOD	0
21	rats	rat	I-NP	NNS	O	14	PMOD	0
22	.	.	O	.	O	6	P	0

1	Furthermore	Furthermore	B-ADVP	RB	O	5	VMOD	0
2	,	,	O	,	O	5	P	0
3	GK	GK	B-NP	NN	O	4	NMOD	0
4	rats	rat	I-NP	NNS	O	5	SUB	0
5	were	be	B-VP	VBD	O	0	ROOT	0
6	treated	treat	I-VP	VBN	O	7	NMOD	19	treated
7	s.c	s.c	B-NP	NN	O	5	PRD	0
8	twice	twice	B-ADVP	RB	O	7	NMOD	0
9	daily	daily	I-ADVP	RB	O	8	AMOD	0
10	with	with	B-PP	IN	O	7	NMOD	0
11	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	10	PMOD	0
12	(	(	O	(	O	7	NMOD	0
13	Kineret	Kineret	B-NP	NNP	O	21	NMOD	0
14	,	,	O	,	O	21	P	0
15	Amgen	Amgen	B-NP	NNP	O	18	NMOD	0
16	,	,	O	,	O	18	P	0
17	100	100	B-NP	CD	O	18	NMOD	0
18	mg/kg/day	mg/kg/day	I-NP	NN	O	21	NMOD	0
19	)	)	O	)	O	18	NMOD	0
20	or	or	O	CC	O	21	NMOD	0
21	saline	saline	B-NP	NN	O	12	PMOD	0
22	,	,	O	,	O	21	P	0
23	from	from	B-PP	IN	O	21	NMOD	0
24	4	4	B-NP	CD	O	25	NMOD	0
25	weeks	week	I-NP	NNS	O	23	PMOD	0
26	of	of	B-PP	IN	O	25	NMOD	0
27	age	age	B-NP	NN	O	28	NMOD	0
28	onwards	onward	I-NP	NNS	O	26	PMOD	0
29	(	(	O	(	O	33	DEP	0
30	onset	onset	B-NP	NN	O	33	DEP	0
31	of	of	B-PP	IN	O	30	NMOD	0
32	diabetes	diabetes	B-NP	NN	O	31	PMOD	0
33	)	)	O	)	O	25	NMOD	0
34	.	.	O	.	O	5	P	0

1	Four	Four	B-NP	CD	O	2	NMOD	0
2	weeks	week	I-NP	NNS	O	11	SUB	0
3	later	later	B-ADVP	RB	O	11	VMOD	0
4	,	,	O	,	O	11	P	0
5	islet	islet	B-NP	NN	O	7	NMOD	0
6	gene	gene	I-NP	NN	O	7	NMOD	0
7	analysis	analysis	I-NP	NN	O	10	NMOD	0
8	and	and	O	CC	O	10	NMOD	0
9	pancreas	pancreas	B-NP	NN	O	10	NMOD	0
10	immunochemistry	immunochemistry	I-NP	NN	O	11	SUB	0
11	were	be	B-VP	VBD	O	0	ROOT	0
12	performed	perform	I-VP	VBN	O	11	VC	0
13	.	.	O	.	O	11	P	0

1	Thirty-two	Thirty-two	B-NP	CD	O	2	NMOD	0
2	genes	gene	I-NP	NNS	O	3	SUB	0
3	were	be	B-VP	VBD	O	0	ROOT	0
4	selected	select	I-VP	VBN	O	3	VC	0
5	encoding	encode	B-VP	VBG	O	4	VMOD	0
6	molecules	molecule	B-NP	NNS	O	5	OBJ	0
7	involved	involve	B-VP	VBN	O	6	NMOD	0
8	in	in	B-PP	IN	O	7	VMOD	0
9	endothelial	endothelial	B-NP	JJ	B-cell_type	11	NMOD	0
10	cell	cell	I-NP	NN	I-cell_type	11	NMOD	0
11	activation	activation	I-NP	NN	O	24	NMOD	17	activation
12	,	,	O	,	O	24	P	0
13	particularly	particularly	B-NP	RB	O	14	NMOD	0
14	fibrinolysis	fibrinolysis	I-NP	NN	O	24	NMOD	0
15	,	,	O	,	O	24	P	0
16	vascular	vascular	B-NP	JJ	O	17	NMOD	0
17	tone	tone	I-NP	NN	O	24	NMOD	0
18	,	,	O	,	O	24	P	0
19	OS	OS	B-NP	NN	O	24	NMOD	0
20	,	,	O	,	O	24	P	0
21	angiogenesis	angiogenesis	B-NP	NN	O	24	NMOD	3	angiogenesis
22	and	and	O	CC	O	24	NMOD	0
23	also	also	B-ADVP	RB	O	24	NMOD	0
24	inflammation	inflammation	B-NP	NN	O	8	PMOD	0
25	.	.	O	.	O	3	P	0

1	All	All	B-NP	DT	O	2	NMOD	0
2	genes	gene	I-NP	NNS	O	30	SUB	0
3	except	except	B-PP	IN	O	2	NMOD	0
4	those	those	B-NP	DT	O	3	PMOD	0
5	encoding	encode	B-VP	VBG	O	4	NMOD	0
6	angiotensinogen	angiotensinogen	B-NP	NN	O	9	NMOD	0
7	and	and	I-NP	CC	O	9	NMOD	0
8	epoxide	epoxide	I-NP	NN	B-protein	9	NMOD	0
9	hydrolase	hydrolase	I-NP	NN	I-protein	22	NMOD	0
10	(	(	O	(	O	9	NMOD	0
11	that	that	B-NP	WDT	O	9	NMOD	0
12	were	be	B-VP	VBD	O	11	SBAR	0
13	decreased	decrease	I-VP	VBN	O	12	VC	18	decreased
14	)	)	O	)	O	13	VMOD	0
15	,	,	O	,	O	9	P	0
16	and	and	O	CC	O	17	NMOD	0
17	12-lipoxygenase	12-lipoxygenase	B-NP	NN	B-protein	22	NMOD	0
18	and	and	O	CC	O	22	NMOD	0
19	vascular	vascular	B-NP	JJ	B-protein	22	NMOD	0
20	endothelial	endothelial	I-NP	JJ	I-protein	22	NMOD	0
21	growth	growth	I-NP	NN	I-protein	22	NMOD	0
22	factor	factor	I-NP	NN	I-protein	5	OBJ	0
23	(	(	O	(	O	22	NMOD	0
24	that	that	B-NP	WDT	O	22	NMOD	0
25	showed	show	B-VP	VBD	O	24	SBAR	0
26	no	no	B-NP	DT	O	27	NMOD	0
27	change	change	I-NP	NN	O	25	OBJ	0
28	)	)	O	)	O	2	NMOD	0
29	,	,	O	,	O	2	P	0
30	were	be	B-VP	VBD	O	0	ROOT	0
31	significantly	significantly	I-VP	RB	O	30	VMOD	0
32	up-regulated	up-regulate	I-VP	VBN	O	30	VC	17	up-regulated
33	in	in	B-PP	IN	O	32	VMOD	0
34	GK	GK	B-NP	NN	B-cell_type	35	NMOD	0
35	islets	islet	I-NP	NNS	I-cell_type	33	PMOD	0
36	.	.	O	.	O	30	P	0

1	After	After	B-PP	IN	O	17	VMOD	0
2	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	3	NMOD	0
3	treatment	treatment	I-NP	NN	O	1	PMOD	19	treatment
4	of	of	B-PP	IN	O	3	NMOD	0
5	GK	GK	B-NP	NN	O	6	NMOD	0
6	rats	rat	I-NP	NNS	O	4	PMOD	0
7	in	in	B-ADVP	FW	O	3	NMOD	0
8	vivo	vivo	I-ADVP	FW	O	7	AMOD	0
9	,	,	O	,	O	17	P	0
10	most	most	B-NP	RBS	O	11	AMOD	0
11	selected	select	I-NP	VBN	O	12	NMOD	0
12	genes	gene	I-NP	NNS	O	17	SUB	0
13	implied	imply	B-VP	VBN	O	12	NMOD	0
14	in	in	B-PP	IN	O	13	VMOD	0
15	endothelium/OS/immune	endothelium/OS/immune	B-NP	JJ	O	16	NMOD	0
16	cells/fibrosis	cells/fibrosi	I-NP	NNS	O	14	PMOD	0
17	were	be	B-VP	VBD	O	0	ROOT	0
18	significantly	significantly	I-VP	RB	O	17	VMOD	0
19	down-regulated	down-regulate	I-VP	VBN	O	17	VC	0
20	.	.	O	.	O	17	P	0

1	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	3	SUB	0
2	also	also	B-ADVP	RB	O	3	VMOD	0
3	improved	improve	B-VP	VBD	O	0	ROOT	17	improved
4	islet	islet	B-NP	NN	O	5	NMOD	0
5	vascularization	vascularization	I-NP	NN	O	3	OBJ	3	vascularization
6	,	,	O	,	O	3	P	0
7	reduced	reduce	B-VP	VBD	O	3	VMOD	0
8	fibrosis	fibrosis	B-NP	NN	O	7	OBJ	0
9	and	and	O	CC	O	7	VMOD	0
10	ameliorated	ameliorate	B-NP	VBN	O	11	NMOD	0
11	glycemia	glycemia	I-NP	NN	O	7	OBJ	0
12	.	.	O	.	O	3	P	0

1	CONCLUSIONS/SIGNIFICANCE	CONCLUSIONS/SIGNIFICANCE	B-NP	NN	O	5	NMOD	0
2	:	:	O	:	O	1	P	0
3	GK	GK	B-NP	NN	O	5	NMOD	0
4	rat	rat	I-NP	NN	O	5	NMOD	0
5	islets	islet	I-NP	NNS	O	6	SUB	0
6	have	have	B-VP	VBP	O	0	ROOT	0
7	increased	increase	I-VP	VBN	O	6	VC	0
8	mRNA	mRNA	B-NP	NN	B-RNA	9	NMOD	0
9	expression	expression	I-NP	NN	O	7	OBJ	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	markers	marker	B-NP	NNS	O	10	PMOD	0
12	of	of	B-PP	IN	O	11	NMOD	0
13	early	early	B-NP	JJ	O	17	NMOD	0
14	islet	islet	I-NP	NN	O	17	NMOD	0
15	endothelial	endothelial	I-NP	JJ	O	17	NMOD	0
16	cell	cell	I-NP	NN	O	17	NMOD	0
17	activation	activation	I-NP	NN	O	12	PMOD	17	activation
18	,	,	O	,	O	17	P	0
19	possibly	possibly	B-VP	RB	O	20	VMOD	0
20	triggered	trigger	I-VP	VBN	O	17	NMOD	0
21	by	by	B-PP	IN	O	20	VMOD	0
22	several	several	B-NP	JJ	O	21	PMOD	0
23	metabolic	metabolic	I-NP	JJ	B-protein	24	NMOD	0
24	factors	factor	I-NP	NNS	I-protein	22	NMOD	0
25	,	,	O	,	O	7	P	0
26	and	and	O	CC	O	7	VMOD	0
27	also	also	B-ADVP	RB	O	7	VMOD	0
28	some	some	B-NP	DT	O	30	NMOD	0
29	defense	defense	I-NP	NN	O	30	NMOD	0
30	mechanisms	mechanism	I-NP	NNS	O	7	VMOD	0
31	.	.	O	.	O	6	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	beneficial	beneficial	I-NP	JJ	O	3	NMOD	0
3	effect	effect	I-NP	NN	O	0	ROOT	0
4	of	of	B-PP	IN	O	3	NMOD	0
5	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	4	PMOD	0
6	on	on	B-PP	IN	O	3	NMOD	0
7	most	most	B-NP	JJS	O	11	NMOD	0
8	islet	islet	I-NP	NN	O	11	NMOD	0
9	endothelial/OS/immune	endothelial/OS/immune	I-NP	JJ	O	11	NMOD	0
10	cells/fibrosis	cells/fibrosis	I-NP	NN	O	11	NMOD	0
11	parameters	parameter	I-NP	NNS	O	6	PMOD	0
12	analyzed	analyze	B-VP	VBN	O	11	NMOD	0
13	highlights	highlight	B-NP	NNS	O	17	NMOD	0
14	a	a	B-NP	DT	O	17	NMOD	0
15	major	major	I-NP	JJ	O	17	NMOD	0
16	endothelial-related	endothelial-related	I-NP	JJ	O	17	NMOD	0
17	role	role	I-NP	NN	O	12	OBJ	16	role
18	for	for	B-PP	IN	O	17	NMOD	0
19	IL-1	IL-1	B-NP	NN	B-protein	18	PMOD	0
20	in	in	B-PP	IN	O	17	NMOD	0
21	GK	GK	B-NP	NN	O	23	NMOD	0
22	islet	islet	I-NP	NN	O	23	NMOD	0
23	alterations	alteration	I-NP	NNS	O	20	PMOD	2	alterations
24	.	.	O	.	O	3	P	0

1	Thus	Thus	B-ADVP	RB	O	6	VMOD	0
2	,	,	O	,	O	6	P	0
3	metabolically-altered	metabolically-altered	B-NP	JJ	O	5	NMOD	16	altered
4	islet	islet	I-NP	NN	O	5	NMOD	0
5	endothelium	endothelium	I-NP	NN	O	6	SUB	0
6	might	might	B-VP	MD	O	0	ROOT	0
7	affect	affect	I-VP	VB	O	6	VC	16	affect
8	the	the	B-NP	DT	O	10	NMOD	0
9	beta-cell	beta-cell	I-NP	NN	O	10	NMOD	0
10	microenvironment	microenvironment	I-NP	NN	O	7	OBJ	0
11	and	and	O	CC	O	7	VMOD	0
12	contribute	contribute	B-VP	VBP	O	7	VMOD	0
13	to	to	B-PP	TO	O	12	VMOD	0
14	progressive	progressive	B-NP	JJ	O	19	NMOD	0
15	type	type	I-NP	NN	O	19	NMOD	0
16	2	2	I-NP	CD	O	19	NMOD	0
17	diabetic	diabetic	I-NP	JJ	O	19	NMOD	0
18	beta-cell	beta-cell	I-NP	NN	O	19	NMOD	0
19	dysfunction	dysfunction	I-NP	NN	O	13	PMOD	0
20	in	in	B-PP	IN	O	19	NMOD	0
21	GK	GK	B-NP	NN	O	22	NMOD	0
22	rats	rat	I-NP	NNS	O	20	PMOD	0
23	.	.	O	.	O	6	P	0

1	Counteracting	Counteract	B-VP	VBG	O	6	SUB	0
2	islet	islet	B-NP	NN	O	5	NMOD	0
3	endothelial	endothelial	I-NP	JJ	O	5	NMOD	0
4	cell	cell	I-NP	NN	O	5	NMOD	0
5	inflammation	inflammation	I-NP	NN	O	1	OBJ	0
6	might	might	B-VP	MD	O	0	ROOT	0
7	be	be	I-VP	VB	O	6	VC	0
8	one	one	B-NP	CD	O	9	NMOD	0
9	way	way	I-NP	NN	O	7	PRD	0
10	to	to	B-VP	TO	O	11	VMOD	0
11	ameliorate/prevent	ameliorate/prevent	I-VP	VB	O	9	NMOD	0
12	beta-cell	beta-cell	B-NP	NN	O	13	NMOD	0
13	dysfunction	dysfunction	I-NP	NN	O	11	OBJ	0
14	in	in	B-PP	IN	O	11	VMOD	0
15	type	type	B-NP	NN	O	17	NMOD	0
16	2	2	I-NP	CD	O	17	NMOD	0
17	diabetes	diabete	I-NP	NNS	O	14	PMOD	0
18	.	.	O	.	O	6	P	0

